share_log

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target

Benzinga ·  Nov 13, 2024 01:39  · Ratings

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:QNCX) with a Buy and maintains $12 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment